Haemonetics (($HAE)) has held its Q3 earnings call. Read on for the main highlights of the call. The latest earnings call from Haemonetics ...

Mizuho lowered the firm’s price target on Haemonetics (HAE) to $90 from $115 and keeps an Outperform rating on the shares post the earnings ...

Q3 2025 Management View CEO Christopher Simon reported third-quarter revenue of $349 million, a 4% increase on a reported basis, with adjusted EPS rising 14% to $1.19. He highlighted the company's ...

JMP Securities lowered the firm’s price target on Haemonetics (HAE) to $100 from $125 and keeps an Outperform rating on the shares. Haemonetics ...

Haemonetics Corporation’s HAE growth in the fiscal second quarter of 2025 can be attributed to the strong potential of the Plasma franchise. The robust uptake of the NexSys PCS system bodes well ...

Haemonetics Corp (NYSE:HAE) is gaining market share in the plasma segment, particularly in the US and Europe, through technology upgrades and new long-term agreements with BioLife and Grifols.

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems ...